Claims
- 1. A quinolone alkanoic acid of the formula: ##STR53## wherein A is a direct bond, or a C.sub.1-4 -alkylene or C.sub.2-4 -alkenylene group; R.sup.1 is hydrogen or a halogen atom or a C.sub.1-4 -alkyl group; R.sup.2 is hydrogen; R.sup.3 is a hydroxy, amino, hydroxylamino, C.sub.1-6 -alkoxy or phenoxy group; and wherein the benzene ring X may be unsubstituted or substituted by 1 or 2 substituents selected from halogen atoms, C.sub.1-6 -alkyl, C.sub.1-4 -alkoxy, C.sub.1-4 -alkylthio, trifluoromethyl, C.sub.1-3 -alkylenedioxy, nitro, amino, C.sub.1-4 -alkylamino, di-(C.sub.1-4 -alkyl)amino, C.sub.2-4 -alkanoylamino, benzyloxy and hallogenobenzyloxy groups; and wherein the ring Y is an unsubstituted phenyl group or a phenyl group substituted by 1, 2 or 3 substituents selected from halogen atoms, C.sub.1-6 -alkyl, C.sub.1-4 -alkoxy, C.sub.1-4 -allkylthio, C.sub.1-4 -alkylamino, di-(C.sub.1-4 -alkyl)amino, nitro, cyano, trifluoromethyl, C.sub.2-8 -alkoxyalkyl, phenyl and halogenophenyl groups; or wherein the ring Y is a naphthyl, halogenonaphthyl, furyl, pyridyl, or thienyl group; or a pharmaceutically acceptable salt thereof.
- 2. A compound as claimed in claim 1 wherein A is a direct bond, or a methylene, ethylene or propenylene group; R.sup.1 is hydrogen, a fluorine, chlorine or bromine atom, or a methyl or ethyl group; R.sup.2 is hydrogen; R.sup.3 is a hydroxy, amino, hydroxylamino, methoxy, ethoxy, n-butoxy, t-butoxy or a phenoxy group; and wherein the benzene ring X may be unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine and iodine atoms, and methyl, ethyl, n-proply, i-propyl, n-butyl, t-butyl, methoxy, ethoxy, methylthio, trifluoromethyl, methylenedioxy, ethylenedioxy, 2,2-propylenedioxy, nitro, amino, methylamino, dimethylamino, acetamido, benzyloxy and chlorobenzyloxy groups; and wherein the ring Y is an unsubstituted phenyl group or a phenyl group substituted by 1, 2 or 3 substituents selected from fluorine, chlorine, bromine and iodine atoms, methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, methoxy, ethoxy, methylthio, methylamino, dimethylamino, nitro, cyano, trifluoromethyl, n-propoxymethyl, phenyl and chlorophenyl groups; or wherein the ring Y is a naphthyl, chloronaphthyl furyl, thienyl or pyridyl group.
- 3. A compound as claimed in claim 1 wherein R.sup.3 is a hydroxy.
- 4. A pharmaceutical aldose reductase inhibiting composition which comprises a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in claim 1 in pharmaceutically-acceptable form.
- 5. A pharmaceutical composition as claimed in claim 4 which is in the form of a tablet, capsule, suspension or solution.
- 6. A method of inhibiting the enzyme aldose reductase in a warm-blooded animal requiring such treatment which comprises internally administering to the said animal an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof as claimed in claim 1.
- 7. A compound selected from the group consisting of 1-(3-chloro-4-bromobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,5-dichloro-4-bromobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,4-dichlorobenzyl)-6-fluoro-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(4-bromo-benzyl)-6-fluoro-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,4-dichlorobenzyl)-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 6-fluoro-1-(4-iodobenzyl)-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(4-bromo-3-chlorobenzyl)-6-fluoro-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,4-dibromoenzyl)-6-fluoro-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,4-dichlorobenzyl)-6-fluoro-3-methyl-1,2-dihydro-2-oxoquinol-4-ylacetic acid, 1-(3,4-dichlorobenzyl)-6,7-difluoro-1,2-dihydro-2-oxoquinol-4-ylacetic acid, and the pharmaceutically acceptable base addition salts thereof.
- 8. A compound selected from the group consisting of the compound 1-(3,4-dichlorobenzyl)-3-methyl-1,2-dihydro-2-oxoquinol-4-ylacetic acid or a pharmaceutically acceptable base addition salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
11644/75 |
Mar 1975 |
GBX |
|
4204375 |
Oct 1975 |
GBX |
|
Parent Case Info
This is a continuation of application Ser. No. 832,613, filed Sept. 12, 1977, now U.S. Pat. No. 4,138,490 which is a continuation-in-part of Ser. No. 662,685, filed Mar. 1, 1976, now U.S. Pat. No. 4,066,651.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
3772301 |
Strandtmann |
Nov 1973 |
|
Non-Patent Literature Citations (1)
Entry |
Kegasawa et al., "Chemical Abstracts", 1968, vol. 69: 106,760(n). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
832613 |
Sep 1977 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
662685 |
Mar 1976 |
|